Search results for "concentrate"

Valorisation of SWRO brines in a remote island through a circular approach: Techno-economic analysis and perspectives

2022

Nowadays, small remote islands rely heavily on desalination technologies to overcome freshwater scarcity. Unfortunately, these technologies are accompanied by the production of brines which can affect the receiving water bodies i.e., the aquatic ecosystem. Yet, it is extremely appealing how such brines constitute an abundant source of valuable raw materials (such as magnesium). In this work, a novel hybrid system is introduced to capture the value of seawater reverse osmosis (SWRO) brines produced in the minor Sicilian island of Pantelleria. The “Minimal Liquid Discharge” (MLD) process consists of: (i) Nanofiltration NF (separation of bivalent from monovalent ions), (ii) Mg Reactive Crystal…

Clinical effectiveness of platelet concentrates for periodontal regeneration

2016

Direct sunlight facility for testing and research in HCPV

2014

A facility for testing different components for HCPV application has been developed in the framework of "Fotovoltaico ad Alta Efficienza" (FAE) project funded by the Sicilian Regional Authority (PO FESR Sicilia 2007/2013 4.1.1.1). The testing facility is equipped with an heliostat providing a wide solar beam inside the lab, an optical bench for mounting and aligning the HCPV components, electronic equipments to characterize the I-V curves of multijunction cells operated up to 2000 suns, a system to circulate a fluid in the heat sink at controlled temperature and flow-rate, a data logging system with sensors to measure temperatures in several locations and fluid pressures at the inlet and ou…

Long-term stability study of clofarabine injection concentrate and diluted clofarabine infusion solutions

2011

Purpose: The aim of this study was to investigate the physicochemical stability of clofarabine (CAFdA) injection concentrate and ready-to-use CAFdA infusion solutions over a prolonged period of 28 days. Methods: To determine the stability of CAFdA infusion solutions, the injection concentrate (Evoltra®, 1 mg/mL, Genzyme) was diluted either with 0.9% sodium chloride or 5% glucose infusion solution. The resulting concentrations of 0.2 mg/mL or 0.6 mg/mL, respectively, were chosen to represent the lower and upper limit of the ordinary concentration range. Test solutions were stored under refrigeration (2–8°C) or at room temperature either light protected or exposed to light. CAFdA concentrati…

Milchsäure-Bildung und Verteilung in Erythrozytenkonzentraten

2001

MEASURING FIELD RILL ERODIBILITY BY A SIMPLIFIED METHOD

2016

Many process-oriented erosion prediction models reproduce rill erosion as affected by site-specific parameters, as for example, rill erodibility, and thus, their practical application requires the measurement of these parameters or their estimate. The aim of this paper was establishing a method for indirectly measuring field rill erodibility. A simple mathematical approach based on a known soil detachment equation and accounting for the rill erosion dynamic process is applied. Field measurements carried out for seven natural rainfall events occurring at the plots of the Sparacia experimental station, southern Italy, are used for indirectly measuring the rill erodibility of the investigated …

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

Physicochemical stability of irinotecan injection concentrate and diluted infusion solutions in PVC bags

2000

Purpose. To determine the physicochemical stability of irinotecan injection concentrate and irinotecan infusion solutions after dilution in two commonly used infusion fluids (0.9% sodium chloride, 5% dextrose) in PVC bags, stored under refrigeration (2-8°C) or at room temperature either light protected or exposed to light. Methods. Stability of irinotecan injection concentrate was determined in the original amber glass vials. Diluted irinotecan infusion solutions were aseptically prepared by further dilution of irinotecan stock solution with either 0.9% sodium chloride or 5% dextrose in PVC bags, in amounts yielding irinotecan concentrations of 0.4, 1.0, or 2.8 mg/ml. Test solutions were s…

Platelet-rich fibrin for wound healing of palatal donor sites of free gingival grafts: Systematic review and meta-analysis.

2020

Made available in DSpace on 2021-06-25T10:22:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-01-01 Background: Platelet-rich fibrin (PRF) has been referred to as a second-generation platelet concentrate, associated with improvements on the healing of palatal wounds followed by FGG harvesting. The aim of this systematic review and meta-analysis was to assess the complete wound epithelialization and postoperative pain when PRF was used in palatal wounds following free gingival graft (FGG) harvesting. Material and Methods: PubMed (Medline), EMBASE and Scopus were searched by two independent individuals up to and including March 2020 in order to identify controlled and randomized cont…

Using pharmacokinetics for tailoring prophylaxis in people with hemophilia switching between clotting factor products: A scoping review.

2019

Abstract The objective of this scoping review is to summarize the current use of pharmacokinetics for tailoring prophylaxis in hemophilia patients switching between clotting factor products. Patients with hemophilia may require switching of clotting factor concentrates due to a variety of factors, but there have been perceived risks associated with switching, such as inhibitor development or suboptimal protection due to inadequate dosing while titrating treatment. Studies that look at patients switching from one clotting factor concentrate to another are categorized in terms of their primary and/or secondary objectives, notably biosimilarity and comparative pharmacokinetic studies and inhib…